NASDAQ:ACXP Acurx Pharmaceuticals - ACXP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.01 -0.13 (-4.14%) (As of 03/20/2023 08:08 AM ET) Add Compare Share Share Today's Range$3.01▼$3.0150-Day Range$3.14▼$4.2552-Week Range$2.33▼$4.85Volume900 shsAverage Volume37,160 shsMarket Capitalization$35.04 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Acurx Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside365.1% Upside$14.00 Price TargetShort InterestHealthy0.27% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.23Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.99) to ($1.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector544th out of 983 stocksPharmaceutical Preparations Industry252nd out of 480 stocks 3.5 Analyst's Opinion Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Acurx Pharmaceuticals has a forecasted upside of 365.1% from its current price of $3.01.Amount of Analyst CoverageAcurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.27% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently decreased by 33.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACXP. Previous Next 1.0 News and Social Media Coverage News SentimentAcurx Pharmaceuticals has a news sentiment score of -0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Acurx Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 2 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders30.90% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.13% of the stock of Acurx Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acurx Pharmaceuticals are expected to decrease in the coming year, from ($0.99) to ($1.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Acurx Pharmaceuticals (NASDAQ:ACXP) StockAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.Read More Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACXP Stock News HeadlinesMarch 19, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Amgen (AMGN) and Acurx Pharmaceuticals (ACXP)March 18, 2023 | seekingalpha.comAcurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Call TranscriptMarch 20, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 18, 2023 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2022 Earnings Call TranscriptMarch 16, 2023 | msn.comAcurx Pharmaceuticals GAAP EPS of -$0.28 beats by $0.15March 16, 2023 | finance.yahoo.comAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateMarch 15, 2023 | msn.comAcurx Pharmaceuticals's Earnings: A PreviewMarch 15, 2023 | americanbankingnews.comAcurx Pharmaceuticals (ACXP) to Release Quarterly Earnings on ThursdayMarch 20, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 12, 2023 | americanbankingnews.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Down 33.8% in FebruaryMarch 6, 2023 | finance.yahoo.comAcurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business UpdateFebruary 14, 2023 | finance.yahoo.comAcurx is Setting a High Bar for New Treatments in C. diffFebruary 7, 2023 | finance.yahoo.comCEO Spotlight: Acurx Pharmaceuticals CEO Confident His Phase 2b Ibezapolstat Drug Candidate Can Earn Front-Line Designation to Treat C. difficileJanuary 24, 2023 | finance.yahoo.comPresenting on the Emerging Growth Conference on January 25 Register NowJanuary 19, 2023 | finance.yahoo.comAcurx Is Vying for Standard of Care in Treating Primary and Recurrent C. diffJanuary 16, 2023 | finance.yahoo.comAcurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023November 13, 2022 | finance.yahoo.comWe're Keeping An Eye On Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn RateNovember 1, 2022 | finance.yahoo.comAcurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business UpdateOctober 26, 2022 | finance.yahoo.comAcurx Announces Scientific Oral and Poster Presented at IDWeek 2022October 17, 2022 | finance.yahoo.comAcurx Announces Scientific Oral and Poster Presentations at IDWeekSeptember 26, 2022 | finance.yahoo.comNew to The Street TV Announces Corporate Interviews on its 390th Show, Airing on the Fox Business Network, Tonight, Monday, September 26, 2022, at 10:30 PM PTSeptember 23, 2022 | finance.yahoo.comNew to The Street TV Announces its Business Guest Interviews, Episode #388 Airs on Bloomberg TV, Saturday, September 24, 2022, at 6:00 PM ET as Sponsored ProgrammingSeptember 16, 2022 | finance.yahoo.comNew to The Street TV / Newsmax TV Announces its Eight Interviews on This Week's TV Broadcast, Episode #386, September 18, 2022, 10-11 AM ETAugust 4, 2022 | finance.yahoo.comAcurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business UpdateAugust 2, 2022 | finance.yahoo.comAcurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of AmericaAugust 1, 2022 | nasdaq.comMonday 8/1 Insider Buying Report: ARCH, ACXPJuly 27, 2022 | seekingalpha.comAcurx, Pharmaceuticals announces $4.25M direct offeringSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACXP Company Calendar Today3/19/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACXP CUSIPN/A CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+345.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,750,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.35% Return on Assets-118.27% Debt Debt-to-Equity RatioN/A Current Ratio4.55 Quick Ratio9.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book2.55Miscellaneous Outstanding Shares11,640,000Free Float8,011,000Market Cap$36.55 million OptionableNot Optionable Beta-0.92 Key ExecutivesMr. Robert J. DeLuccia (Age 76)Co-Founder & Exec. Chairman Comp: $464.77kMr. David P. Luci CPA (Age 55)CPA, Esq., J.D., Corp. Sec., Co-Founder, Pres, CEO & Director Comp: $443.14kMr. Robert G. Shawah CPA (Age 55)CPA, Co-Founder & CFO Comp: $200.34kKey CompetitorsAquestive TherapeuticsNASDAQ:AQSTGenprexNASDAQ:GNPXMedicenna TherapeuticsNASDAQ:MDNAProMIS NeurosciencesNASDAQ:PMNPurple BiotechNASDAQ:PPBTView All CompetitorsInsiders & InstitutionsArmistice Capital LLCSold 186,000 shares on 2/15/2023Ownership: 7.593%Millennium Management LLCSold 18,290 shares on 2/15/2023Ownership: 0.251%Carl SailerBought 19,737 shares on 7/27/2022Total: $75,000.60 ($3.80/share)View All Insider TransactionsView All Institutional Transactions ACXP Stock - Frequently Asked Questions Should I buy or sell Acurx Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACXP shares. View ACXP analyst ratings or view top-rated stocks. What is Acurx Pharmaceuticals' stock price forecast for 2023? 2 equities research analysts have issued 12 month price objectives for Acurx Pharmaceuticals' shares. Their ACXP share price forecasts range from $14.00 to $14.00. On average, they anticipate the company's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 345.9% from the stock's current price. View analysts price targets for ACXP or view top-rated stocks among Wall Street analysts. How have ACXP shares performed in 2023? Acurx Pharmaceuticals' stock was trading at $3.98 at the beginning of the year. Since then, ACXP shares have decreased by 21.1% and is now trading at $3.14. View the best growth stocks for 2023 here. Are investors shorting Acurx Pharmaceuticals? Acurx Pharmaceuticals saw a drop in short interest in the month of February. As of February 28th, there was short interest totaling 24,900 shares, a drop of 33.8% from the February 13th total of 37,600 shares. Based on an average trading volume of 33,900 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.3% of the company's stock are sold short. View Acurx Pharmaceuticals' Short Interest. When is Acurx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our ACXP earnings forecast. When did Acurx Pharmaceuticals IPO? (ACXP) raised $15 million in an initial public offering on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities acted as the underwriters for the IPO. What is Acurx Pharmaceuticals' stock symbol? Acurx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACXP." Who are Acurx Pharmaceuticals' major shareholders? Acurx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (7.59%), Millennium Management LLC (0.25%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia. View institutional ownership trends. How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acurx Pharmaceuticals' stock price today? One share of ACXP stock can currently be purchased for approximately $3.14. How much money does Acurx Pharmaceuticals make? Acurx Pharmaceuticals (NASDAQ:ACXP) has a market capitalization of $36.55 million. The company earns $-12,750,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. How can I contact Acurx Pharmaceuticals? The official website for the company is www.acurxpharma.com. The company can be reached via phone at 917-533-1469 or via email at davidluci@acurxpharma.com. This page (NASDAQ:ACXP) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.